LONDON (ShareCast) - AIM-listed medical diagnostics company Omega has cheered with news of its infectious disease and allergy projects.
Within infectious disease it has made three pilot batches of test devices all of which have shown that its Visitect CD4 product is capable of meeting its performance design goals in comparison to flow cytometry when tested on HIV positive patients.

As a result, the firm has selected in-house manufacturing processes that are scalable and which will now be subject to verification and validation leading to the release of Visitect CD4 test devices for re-evaluation in the field.

"We remain very confident of the prospective commercial success of Visitect CD4 and will provide further updates in due course," Omega said.

Meanwhile, the allergy development programme has continued to progress. The results of a preliminary field study that compared the firm's Allersys system to its ThermoFisher ImmunoCAP were recently accepted for presentation at the European Academy of Allergy and Clinical Immunology annual meeting.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE